12 Best Defensive Stocks To Buy Right Now

Page 7 of 12

6. Johnson & Johnson (NYSE:JNJ)

Number of Hedge Fund Holders: 81 

Johnson & Johnson (NYSE:JNJ) researches and develops, manufactures, and sells various products in the healthcare field. In the fourth quarter of 2024, J&J reported revenues of $22.52 billion, marking a 5.3% increase from the same period in the previous year. This growth was driven by robust sales in the pharmaceutical and medical technology divisions, which saw increases of 4.4% and 6.7%, respectively. For the full year 2024, the company achieved total revenues of $88.82 billion, reflecting a 4.3% rise compared to 2023. The US market contributed $50.3 billion, an 8.3% increase, while international markets accounted for $38.5 billion, a slight decrease of 0.5% due to unfavorable currency impacts. J&J has a remarkable track record of dividend growth, having increased its annual dividend for 62 consecutive years.

Page 7 of 12